Tirofiban mechanism of action

Tirofiban is a medication used for the treatment of acute coronary syndrome (ACS) and as an adjunctive therapy for percutaneous coronary intervention (PCI). It is a glycoprotein IIb/IIIa inhibitor that works by inhibiting platelet aggregation, ultimately preventing the formation of blood clots. 

Platelet aggregation plays a crucial role in the formation of blood clots, which can lead to serious conditions such as heart attacks and strokes. The glycoprotein IIb/IIIa receptor is a crucial component of platelet aggregation, as it allows platelets to stick to each other and to the walls of blood vessels. Tirofiban specifically targets this receptor, preventing platelets from binding to each other and to the blood vessel walls.

Tirofiban works by binding to the glycoprotein IIb/IIIa receptor on the surface of platelets, thus blocking the receptor's ability to interact with fibrinogen, which is a protein that crosslinks platelets to form blood clots. By inhibiting the glycoprotein IIb/IIIa receptor, tirofiban reduces platelet aggregation and prevents the formation of blood clots.

Tirofiban is an intravenous medication, and its onset of action is very rapid, usually within minutes of administration. The drug has a short half-life of approximately two hours, which allows for quick reversibility of its effects.

In addition to its role in ACS and PCI, tirofiban has been investigated for its potential in other conditions involving platelet activation, such as ischemic stroke and peripheral arterial disease. However, its use in these settings is still under investigation.